Topics

Revance Therapeutics focus on its own Botox biosimilar as work with Mylan is stalled

06:02 EDT 13 Sep 2019 | Generics and Biosimilars Initiative

As Revance gives Mylan more time to decide whether to develop their joint Botox biosimilar, the firm is continuing to focus on its own Botox biosimilar, DAXI. It aims to launch the product in 2020.

Original Article: Revance Therapeutics focus on its own Botox biosimilar as work with Mylan is stalled

NEXT ARTICLE

More From BioPortfolio on "Revance Therapeutics focus on its own Botox biosimilar as work with Mylan is stalled"

Quick Search

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...